The Clinical Outcomes of the Modified Broström vs Anatomic Reconstruction Operation in CLAI and GJL
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Jan 16, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare two different surgical methods for treating ankle sprains and instability. The two procedures being studied are the modified Broström operation and anatomical reconstruction. Researchers want to see which method leads to better recovery and fewer problems for patients suffering from chronic ankle instability.
To participate in this study, individuals must be between 18 and 60 years old and have been diagnosed with ongoing lateral ankle pain and instability. Those who have recently injured their ankle, have specific ligament injuries, or certain other conditions will not be eligible. Participants can expect to receive either of the two surgical procedures and will be monitored to assess their recovery over time. This trial is currently recruiting participants of all genders. If you or someone you know is dealing with chronic ankle issues, this could be an opportunity to receive specialized care while contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of lateral ankle pain and instability Beighton score ≥4 Age with 18 to 60 years
- Exclusion Criteria:
- • Patients with an acute or subacute ankle injury (within 3 months) Injury of the deltoid ligament Alignment of lower extremity greater than 5 degrees Fractures of the lower extremity Stage III or IV osteoarthritis Patients who refused to participate in the study
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Patients applied
Trial Officials
Dong Jiang, MD
Principal Investigator
Peking University Third Hosptial
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials